Yuji Uehara: Morning immuno-chemotherapy nearly doubled survival in NSCLC

Yuji Uehara, Medical Oncologist at National Cancer Center Japan, shared a post on X about a paper by Zhe Huang et al. published in eBioMedicine:

“Timing might matter in NSCLC! A bi-continental study shows morning immuno-chemotherapy (before 11:30 AM) nearly doubled survival vs afternoon dosing (33.0 vs 19.5 months). RWE from France and China – time to rethink the schedule of immunotherapy!”

“Overall survival according to time-of-day of combined immuno-chemotherapy for advanced non-small cell lung cancer: a bicentric bicontinental study”

Authors: Zhe Huang, Abdoulaye Karaboué, Liang Zeng, Yongchang Zhang, Francis Lévi et al.